XML 36 R19.htm IDEA: XBRL DOCUMENT
v3.25.1

Net Income (Loss) Per Share | 6 Months Ended
--- | ---
Mar. 31, 2025
Earnings Per Share [Abstract] |
Net Income (Loss) Per Share | NET INCOME (LOSS) PER SHARE The following table presents the computation of basic and diluted net income (loss) per share for the three and six months ended March 31, 2025 and 2024.
|  | Three Months Ended March 31, |  | Six Months Ended March 31,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
|  | (in thousands, except per share amounts)
Numerator: |  |  |  |  |  |  |  |
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc. |  | $ | 370,445 |  |  | $ | (125,300) |  |  | $ | 197,360 |  |  | $ | (258,164) |
Denominator: |  |  |  |  |  |  |  |
Weighted-average basic shares outstanding (1) |  | 133,363 |  |  | 123,285 |  |  | 129,059 |  |  | 115,307 |
Effect of dilutive securities |  | 1,121 |  |  | — |  |  | 1,206 |  |  | — |
Weighted-average diluted shares outstanding (1) |  | 134,484 |  |  | 123,285 |  |  | 130,265 |  |  | 115,307 |
Basic net income (loss) per share |  | $ | 2.78 |  |  | $ | (1.02) |  |  | $ | 1.53 |  |  | $ | (2.24) |
Diluted net income (loss) per share |  | $ | 2.75 |  |  | $ | (1.02) |  |  | $ | 1.52 |  |  | $ | (2.24) |
(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6. The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net income (loss) per share because to include them would be anti-dilutive.
|  | Three Months Ended March 31, |  | Six Months Ended March 31,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
|  | (in thousands)
Options |  | 760 |  |  | 595 |  |  | 750 |  |  | 657 |
Restricted stock units |  | 5,289 |  |  | 3,411 |  |  | 4,567 |  |  | 3,931 |
Total |  | 6,049 |  |  | 4,006 |  |  | 5,317 |  |  | 4,588 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration